Fortress Biotech Announces Publication of Phase 1 Data on CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia in Biology of Blood and Marrow Transplantation

20 June 2018

Fortress Biotech, formerly Coronado Biosciences Inc, announces publication in the journal Biology of Blood and Marrow Transplantation of positive Phase 1 clinical trial data evaluating technology licensed from UCLB, in the form of CNDO-109-activated allogeneic natural killer (NK) cells, in patients with acute myeloid leukemia (AML).

Learn more here:

2018-06-20T14:08:12+00:00